Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

Neurocrine is nearing a $2.5bn-plus deal to acquire Soleno Therapeutics, the biotech company behind the first commercialized drug for Prader-Willi syndrome, a disorder causing extreme hunger. This acquisition could significantly impact the biotechnology sector and Neurocrine's stock price. The deal reflects the growing interest in rare disease treatments and the potential for significant returns on investment in this area.